{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:19:18Z","timestamp":1785932358688,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ucl.2025.08.001","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T22:24:04Z","timestamp":1760567044000},"page":"595-604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Medical Therapy for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms"],"prefix":"10.1016","volume":"52","author":[{"given":"Alexis E.","family":"Te","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"s3","key":"10.1016\/j.ucl.2025.08.001_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-410X.2008.07497.x","article-title":"BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE","volume":"101","author":"Roehrborn","year":"2008","journal-title":"BJU Int"},{"issue":"25","key":"10.1016\/j.ucl.2025.08.001_bib2","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ucl.2025.08.001_bib3","first-page":"662","article-title":"Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo","volume":"54","author":"Roehrborn","year":"1999","journal-title":"PLESS Study Group. Urology"},{"issue":"2","key":"10.1016\/j.ucl.2025.08.001_bib4","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","article-title":"The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study","volume":"179","author":"Roehrborn","year":"2008","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.08.001_bib5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0090-4295(02)01905-2","article-title":"Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia","volume":"60","author":"Roehrborn","year":"2002","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ucl.2025.08.001_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bju.13033","volume":"116","author":"Roehrborn","year":"2015","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2025.08.001_bib7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","article-title":"Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5\u03b1-reductase inhibitor dutasteride","volume":"44","author":"Barkin","year":"2003","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.ucl.2025.08.001_bib8","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive BladderA randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ucl.2025.08.001_bib9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","article-title":"The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia","volume":"335","author":"Lepor","year":"1996","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2025.08.001_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0302-2838(01)00016-1","article-title":"Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study","volume":"41","author":"van Kerrebroeck","year":"2002","journal-title":"Eur Urol"},{"issue":"Suppl 4","key":"10.1016\/j.ucl.2025.08.001_bib11","first-page":"S42","article-title":"Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia","volume":"7","author":"Narayan","year":"2005","journal-title":"Rev Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.08.001_bib12","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1016\/j.juro.2009.02.034","article-title":"Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies","volume":"182","author":"Marks","year":"2009","journal-title":"J Urol"},{"issue":"Suppl 4","key":"10.1016\/j.ucl.2025.08.001_bib13","first-page":"S22","article-title":"A comparison of varying \u03b1-blockers and other pharmacotherapy options for lower urinary tract symptoms","volume":"7","author":"Chapple","year":"2005","journal-title":"Rev Urol"},{"issue":"2","key":"10.1016\/j.ucl.2025.08.001_bib14","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1569-9056(04)90505-2","article-title":"Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience","volume":"29","author":"Chapple","year":"1996","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.08.001_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000019919","article-title":"A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction","volume":"36","author":"Djavan","year":"1999","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2025.08.001_bib16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.ju.0000097026.43866.cc","article-title":"Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia","volume":"171","author":"Roehrborn","year":"2004","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.ucl.2025.08.001_bib17","first-page":"S14","article-title":"Side effects of \u03b1-blocker use: retrograde ejaculation","volume":"11","author":"Kaplan","year":"2009","journal-title":"Rev Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.08.001_bib18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcrs.2005.02.027","article-title":"Intraoperative floppy iris syndrome associated with tamsulosin","volume":"31","author":"Chang","year":"2005","journal-title":"J Cataract Refract Surg"},{"issue":"3","key":"10.1016\/j.ucl.2025.08.001_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0090-4295(02)02401-9","article-title":"Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia","volume":"61","author":"Wessells","year":"2003","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.ucl.2025.08.001_bib20","first-page":"203","article-title":"Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase","volume":"7","author":"Marihart","year":"2005","journal-title":"Rev Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.08.001_bib21","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1210\/jc.2003-030330","article-title":"Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor","volume":"89","author":"Clark","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ucl.2025.08.001_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2025.08.001_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003698","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023","volume":"211","author":"Sandhu","year":"2024","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.08.001_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.08.001_bib25","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.eururo.2011.08.005","article-title":"Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial","volume":"60","author":"Porst","year":"2011","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2025.08.001_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","article-title":"Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial","volume":"61","author":"Oelke","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2025.08.001_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1743-6109.2011.02504.x","article-title":"Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study","volume":"9","author":"Egerdie","year":"2012","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.ucl.2025.08.001_bib28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.juro.2009.11.014","article-title":"Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial","volume":"183","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.08.001_bib29","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.urology.2009.09.093","article-title":"Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction","volume":"75","author":"Broderick","year":"2010","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.ucl.2025.08.001_bib30","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.juro.2013.09.059","article-title":"Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia","volume":"191","author":"Casab\u00e9","year":"2014","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2025.08.001_bib31","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","article-title":"Mirabegron Add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH)","volume":"6","author":"Kakizaki","year":"2020","journal-title":"European Urology Focus"},{"issue":"2","key":"10.1016\/j.ucl.2025.08.001_bib32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.eururo.2008.06.032","article-title":"Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size","volume":"55","author":"Roehrborn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2025.08.001_bib33","article-title":"Role of antimuscarinics combined with alpha-blockers in the management of urinary storage symptoms in patients with benign prostatic hyperplasia: an updated systematic review and meta-analysis","author":"Lenfant","year":"2023","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2025.08.001_bib34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJMoa053085","article-title":"Saw palmetto for benign prostatic hyperplasia","volume":"354","author":"Bent","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ucl.2025.08.001_bib35","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.2011.1364","article-title":"Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial","volume":"306","author":"Barry","year":"2011","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ucl.2025.08.001_bib36","first-page":"CD001423","article-title":"Serenoa repens for benign prostatic hyperplasia","volume":"2012","author":"Tacklind","year":"2012","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014325000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T22:25:26Z","timestamp":1760567126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014325000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0094014325000692"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2025.08.001","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Therapy for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2025.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}